title: Feline immunodeficiency virus subunit vaccines that induce virus neutralising antibodies but no protection against challenge infection.
abstract: Three experimental vaccines against feline immunodeficiency virus (FIV), all based on viral antigens presented via immune stimulating complexes (iscoms), were tested for their capacity to induce protection in cats from FIV infection. The respective vaccines consisted of FIV propagated in Crandell feline kidney (CrFK) cells (FIV-iscoms); FIV-iscoms spiked with recombinant vaccinia virus expressed FIV envelope glycoprotein incorporated into iscoms (FIV-iscoms + vGR657x15-iscoms) and vGR657x15-iscoms spiked with recombinant FIV Gag protein incorporated into iscoms (vGR657x15-iscoms + FIV-Gag-iscoms). Simian immunodeficiency virus envelope glycoprotein incorporated into iscoms, iscoms prepared with uninfected CrFK cells, and PBS served as controls. All cats vaccinated with vGR657x15-iscoms combined with FIV-iscoms or FIV-Gag-iscoms developed Env-specific plasma antibody responses. These antibodies neutralised FIV infection in CrFK cells, but failed to neutralise FIV infection in primary feline thymocytes. FIV-iscoms induced poor Env-specific responses and only one out of six cats developed antibodies that neutralised FIV in the CrFK cell based assay. Four weeks after challenge all cats proved to be infected, showing that none of the vaccine preparations provided protection. In contrast, 2 weeks after infection, virus infected peripheral blood mononuclear cells were only observed in cats vaccinated with FIV-iscoms + vGR657x15-iscoms or CrFK-iscoms and to a lesser extent in cats vaccinated with FIV-iscoms and vGR657x15-iscoms + FIV-Gag-iscoms, but not in cats vaccinated with SIV-iscoms or PBS. The differences found in cell associated virus loads amongst the respective groups are discussed in the light of antibody mediated enhancement of infectivity and protective effects provided by Gag-specific T cell responses.
authors.affiliation: Institute of Virology, Erasmus University Rotterdam, The Netherlands.
authors.forename: W
authors.initials: W
authors.lastname: Huisman
authors.forename: J A
authors.initials: JA
authors.lastname: Karlas
authors.forename: K H
authors.initials: KH
authors.lastname: Siebelink
authors.forename: R C
authors.initials: RC
authors.lastname: Huisman
authors.forename: A
authors.initials: A
authors.lastname: de Ronde
authors.forename: M J
authors.initials: MJ
authors.lastname: Francis
authors.forename: G F
authors.initials: GF
authors.lastname: Rimmelzwaan
authors.forename: A D
authors.initials: AD
authors.lastname: Osterhaus
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D000956:Antigens, Viral / Q000276:immunology; D002415:Cats; D016089:Immunodeficiency Virus, Feline / Q000276:immunology*; D016180:Lentivirus Infections / Q000276:immunology / Q000517:prevention & control*; D014611:Vaccination; D014765:Viral Vaccines / Q000008:administration & dosage*; D014766:Viremia / Q000276:immunology / Q000517:prevention & control
chemical_list: D000914:Antibodies, Viral; D000956:Antigens, Viral; D014765:Viral Vaccines